Global Dermatophytic Onychomycosis Therapeutics Market Report
DUBLIN, Apr. 10, 2014 /PRNewswire/ --Research and Markets (http://www.researchandmarkets.com/research/pnf52x/global) has announced the addition of the "Global Dermatophytic Onychomycosis Therapeutics Market Report" report to their offering.
(Logo: http://photos.prnewswire.com/prnh/20130307/600769)
The analysts forecast the Global Dermatophytic Onychomycosis Therapeutics market to grow at a CAGR of 7.28 percent over the period 2012-2016. One of the key factors contributing to this market growth is the strong and promising pipeline. The Global Dermatophytic Onychomycosis Therapeutics market has also been witnessing an increased focus on combination therapies for the treatment of dermatophytic onychomycosis. However, the adverse side effects associated with drugs could pose a challenge to the growth of this market.
The report, Global Dermatophytic Onychomycosis Therapeutics Market Report, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Dermatophytic Onychomycosis Therapeutics market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
A current trend witnessed in the Global Dermatophytic Onychomycosis Therapeutics market is the use of combination therapies for treating dermatophytic onychomycosis. It has been found that a combination of topical and systemic treatment increases the cure rate when compared to the single therapy. A combination of amorolfine nail lacquer and oral terbinafine is the most commonly used combination therapy.
It has improved clinical efficiency and is more cost-effective than terbinafine alone. At times the combination of surgery and systemic and topical therapies are also used in treatment. Moreover, sometimes non-pharmacological approaches such as laser treatment; mechanical treatment is also used in combination with topical and systemic therapy. This trend will have a positive impact on the growth of the market.
According to the report, the growth of the Global Dermatophytic Onychomycosis Therapeutics market is driven by several factors, the most important of which is the strong and promising pipeline of drugs that have disease-modifying properties and a better safety and efficacy profile.
Further, the report states that one of the key challenges in the market is the risk of side effects associated with dermatophytic onychomycosis drugs. These side effects are hampering the acceptance of advanced drugs for the treatment of moderate to severe dermatophytic onychomycosis.
The report also includes a discussion of the other vendors operating in this market. The other vendors in the market are Celtic Pharmaceutical Holdings L.P., Genelabs Technologies Inc., Hisamitsu Pharmaceutical Co. Inc., Mayne Pharma Ltd., Merck & Co. Inc., NanoBio Corp., Palau Pharma S.A., Promius Pharma LLC, Stiefel Laboratories Inc., Topica Pharmaceuticals Inc., and Valeant Pharmaceuticals International.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Key Topics Covered:
1. Executive Summary
2. Scope of the Report
3. Market Research Methodology
4. List of Abbreviations
5. Introduction
6. Types of Dermatophytic Onychomycosis
7. Currently Approved Drugs
8. Market Landscape
9. Geographical Segmentation
10. Rate of Incidence and Prevalence
11. Pipeline Analysis
12. Buying Criteria
13. Market Growth Drivers
14. Drivers and their Impact
15. Market Challenges
16. Impact of Drivers and Challenges
17. Market Trends
18. Trends and their Impact
19. Vendor Landscape
20. Key Vendor Analysis
21. Other Reports in this Series
Companies Mentioned:
- Anacor Pharmaceuticals Inc.
- Celtic Pharmaceutical Holdings L.P.
- Genelabs Technologies Inc.
- Hisamitsu Pharmaceutical Co. Inc.
- Janssen Biotech Inc.
- Mayne Pharma Ltd.
- Merck & Co. Inc.
- NanoBio Corp.
- Novartis International AG
- Palau Pharma S.A.
- Pfizer Inc.
- Promius Pharma LLC
- Stiefel laboratories Inc.
- Topica Pharmaceuticals Inc.
- Valeant Pharmaceuticals International
For more information visit http://www.researchandmarkets.com/research/pnf52x/global
Media Contact:Laura Wood , +353-1-481-1716, press@researchandmarkets.net
Share this article